DNTH vs HRMY: which is the better buy in 2026?
On Alexandria's Compass, Dianthus Therapeutics, Inc. has the edge with a 90/100 score versus 88/100 for HRMY. Here is how they stack up, factor by factor.
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Claseprubart is shaping up as the next-generation complement franchise, with gMG data due to reset how the Street values C1s inhibition.
Full DNTH analysisHarmony Biosciences Holdings, Inc.
NASDAQ:HRMY
A cash-gushing rare disease franchise trading at 6x forward earnings while the market waits for pitolisant to escape narcolepsy.
Full HRMY analysisFactor by factor
Get head-to-heads like this, free
Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is DNTH or HRMY the better buy in 2026?
By Compass Score, Dianthus Therapeutics, Inc. (NASDAQ:DNTH) edges it at 90/100 versus 88/100 for HRMY. Both scores update weekly and reflect a contrarian, forward-looking read, not a recommendation.
How does Alexandria compare DNTH and HRMY?
Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.
Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.